|
报告导航:研究报告—
生命科学—生物科技
|
2012-2015年中国血液制品行业研究报告 |
 |
字数:3.8万 |
页数:115 |
图表数:131 |
中文电子版:8500元 |
中文纸版:4250元 |
中文(电子+纸)版:9000元 |
英文电子版:2400美元 |
英文纸版:2500美元 |
英文(电子+纸)版:2700美元 |
编号:ZYM042
|
发布日期:2013-07 |
附件:下载 |
 |
|
血浆是血液制品行业的关键原料。2011年8月中国关停贵州16家血浆站,造成当年投浆量同比下降15%。但受利好政策的实施、供求紧张的加剧以及产品价格上涨等因素推动,2012年中国150多家血浆站,投浆量约3600吨,同比增长14.2%。 2012-2013年中期,中国部分企业新浆站已开始采浆或取得采浆许可,如博雅生物的岳池浆站、华兰生物的长垣浆站以及中国生物制品的曹县浆站等,预计2013年以后中国血浆¬供应紧张局面会进一步缓解。 从中检所批发签数据看,2012年1-10月中国血液制品¬批发签总量约3613万瓶,较2011全年增长7.1%。并且,除了人凝血因子VIII的批签发数量有所降低外,其他产品均呈现增长态势。其中人免疫球蛋白、破伤风免疫球蛋白、人纤维蛋白原、进口人血白蛋白同比增幅较高,2012年1-10月分别达到321%、95%、79%、45%。但是,目前中国血液制品企业研发能力弱、血浆利用率很低、产品品种仍相对较少。国内市场仍主要以技术要求不高的人血白蛋白和静注人免疫球蛋白(ph4)为主,2012年这两种产品的批发签量合计占比60%以上。 为了弥补国内血液制品供求紧张,近年中国已允许人血白蛋白和重组凝血因子VIII的进口。其中,人血白蛋白则凭借价格较低优势,进口上升趋势明显。2012年1-10月批发签量达到851万瓶,占同期该类产品批发签量的47.5%(2011年占比43.3%);并且进口企业Behring、Baxter、基立福和奥克特珐玛的批发签量居该类产品前四。但重组凝血因子VIII由于价格昂贵且受国家政策限制,目前进口很少,截止2012年底只批准了拜耳和百特产品进口。 《2012-2015年中国血液制品行业研究报告》主要包括以下几个内容:- 中国血液制品行业的投浆量、浆站分布、市场规模以及市场供需等;
- 中国血液制品行业的竞争格局、政策环境以及进出口等;
- 中国人血白蛋白、静注人免疫球蛋白(ph4)、凝血因子等8类血液制品的市场供需及竞争格局等;
- 中国12家本土血液制品生产企业的发展现状、运营能力以及血浆站和产品批发签情况等。
截止2012年底,中国通过 GMP 认证并正常经营的约30家,其中年投浆量在300吨以上的仅有华兰生物、天坛生物(包括成都蓉生)、上海莱士、远大蜀阳、中国生物制品等少数几家。2012年这五家企业的投浆量约占全国总投浆量的56.1%;营业收入合计占同期中国血液制品市场的30%左右。 广东双林生物排名第六,2012年公司浆站数达9家(3个在建),投浆量247吨左右,血液制品收入4.31亿元,并且公司的狂犬病免疫球蛋白批发签量占比近年一直稳居第一。江西博雅生物虽然目前市场份额较小,2012年市场份额达1.8%(按销售额),但是其拥有7家浆站储备,未来浆站及血液制品产销将有进一步提高。
Plasma is a key raw material of the blood product industry. In August
2011, China shut down 16 plasma stations in Guizhou, resulting in a
decrease of 15% in the plasma volume of the year. However, due to the
implementation of favorable policies, widening gap between supply and
demand, rising product prices and other factors, more than 150 plasma
stations in China produced about 3,600 tons of plasma in 2012, up 14.2%
year on year. From 2012 to mid-2013, new plasma stations of some Chinese
enterprises have started plasma collection or obtained plasma
collection permits, such as Yuechi plasma station of Jiangxi Boya
Bio-Pharmaceutical, Changyuan plasma station of Hualan Bio, and Caoxian
plasma station of China Biologic Products. It’s expected that China’s
plasma supply tension will be further eased after 2013. According
to the lot release statistics of National Institutes for Food and Drug
Control, in the first ten months of 2012, China’s total lot release
volume of blood products was about 36.13 million bottles, an increase of
7.1% compared with the full year of 2011. In addition, except human
coagulation factor VIII with a decreased lot release volume, other
products saw growing release volume. In particular, human
immunoglobulin, tetanus immunoglobulin, human fibrinogen, imported human
serum albumin witnessed higher growth rates of 321%, 95%, 79%, 45%
respectively in the first ten months of 2012. However, Chinese blood
product enterprises have weak R&D capability, low plasma utilization
and fewer product varieties. The domestic market is still dominated by
technically undemanding human serum albumin and human immunoglobulin
(ph4) for intravenous injection, which accounted for more than 60% of
the lot release volume in 2012. In order to ease the domestic
shortage of blood products, China has allowed the import of human serum
albumin and recombinant coagulation factor VIII in recent years. Human
serum albumin imports have grown rapidly due to low prices. The lot
release volume was 8.51 million bottles in the first ten months of 2012,
occupying 47.5% of the lot release volume of such products (43.3% in
2011); Behring, Baxter, Instituto Grifols and Octapharma were top four
companies by lot release volume. However, due to high prices and
national policy restrictions, the import of recombinant coagulation
factor VIII is very small, only Bayer and Baxter products were allowed
to be imported as of the end of 2012. China Blood Product Industry Report, 2012-2015 covers the followings:  Plasma volume, plasma station distribution, market size and supply & demand of China blood product industry;  Competition pattern, policy environment and import & export of China blood product industry; 
Market supply & demand and competition pattern of eight categories
of blood products including human serum albumin, human immunoglobulin
(ph4) for intravenous injection, coagulation factors in China;  Development, operation, plasma stations and lot release volume of 12 local blood product producers in China. As
of the end of 2012, there were about 30 enterprises passing GMP
certification and in normal operation, among them, only Hualan Bio,
Tiantan Biological Products (including Chengdu Ronsen), Shanghai RAAS,
Yuanda Shuyang Pharmaceutical, China Biologic Products have an annual
plasma volume of over 300 tons. In 2012, the five enterprises accounted
for 56.1% of China’s total plasma volume, and about 30% of China’s blood
product market revenue. Guangdong Shuanglin Bio-pharmacy, the
sixth place holder, had nine plasma stations (three under construction)
in 2012, with a plasma volume of about 247 tons and blood product
revenue of RMB 431 million. The company has held the largest lot release
volume of rabies immunoglobulin in recent years. Jiangxi Boya, though
occupying a small market share (1.8% in 2012 by sales), has seven plasma
stations, with output and sales volume expected to be further enhanced
in the future.
正文 目录 第一章 血液制品行业概述 1.1血液制品定义 1.2血液制品分类 1.3重组血液制品 1.4血液制品产业链 1.5血液制品特点
第二章 中国血液制品行业总体概述 2.1市场规模 2.2发展现状 2.3 市场供需 2.3.1 市场供给 2.3.2 市场需求 2.4 市场竞争 2.5运行环境 2.5.1国际市场 2.5.2政策环境 2.5.3国内生物制药市场 2.6进出口分析
第三章 中国血液制品细分市场分析 3.1人血白蛋白 3.1.1 市场供需 3.1.2 竞争格局 3.1.3 发展前景 3.2静注人免疫球蛋白(ph4) 3.2.1 市场供需 3.2.2竞争格局 3.3凝血因子VIII 3.3.1 市场供需 3.3.2 竞争格局 3.3.3 发展前景 3.4乙肝免疫球蛋白 3.4.1 市场供需 3.4.2竞争格局 3.5人免疫球蛋白 3.5.1 市场供需 3.5.2 竞争格局 3.6人凝血酶原复合物 3.6.1 市场供需 3.6.2竞争格局 3.7破伤风免疫球蛋白 3.7.1 市场供需 3.7.2竞争格局 3.8狂犬病人免疫球蛋白 3.8.1 市场供需 3.8.2 竞争格局
第四章 国内主要厂商 4.1中国生物制品有限公司 4.1.1公司简介 4.1.2经营状况 4.1.3 营收构成 4.1.4 客户及供应商 4.1.5 研发与投资 4.1.6 山东泰邦生物制品有限公司 4.1.7 贵阳黔峰生物制品有限责任公司 4.1.8 西安回天血液制品有限责任公司 4.1.9 前景及预测 4.2华兰生物工程股份有限公司 4.2.1公司简介 4.2.2 经营状况 4.2.3 营收构成 4.2.4 毛利率 4.2.5 客户及供应商 4.2.6 研发及投资 4.2.7 血液制品 4.2.8 前景及预测 4.3上海莱士血液制品股份有限公司 4.3.1 公司简介 4.3.2 经营状况 4.3.3 营收构成 4.3.4 毛利率 4.3.5 客户及供应商 4.3.6 研发及投资 4.3.7 前景及预测 4.4北京天坛生物制品股份有限公司 4.4.1公司介绍 4.4.2 经营状况 4.4.3 营收构成 4.4.4 毛利率 4.4.5 客户及供应商 4.4.6 研发与投资 4.4.7 血液制品(成都蓉生药业有限公司) 4.4.8 前景及预测 4.5振兴生化股份有限公司 4.5.1 公司简介 4.5.2 经营状况 4.5.3 营收构成 4.5.4 毛利率 4.5.5 客户及供应商 4.5.6 研发及投资 4.5.7 血液制品(广东双林生物制药有限公司) 4.5.8 前景及预测 4.6江西博雅生物制药有限公司 4.6.1公司介绍 4.6.2经营状况 4.6.3 营收构成 4.6.4 毛利率 4.6.5 客户及供应商 4.6.6 研发及投资 4.6.7 前景及预测 4.7四川远大蜀阳药业 4.7.1公司介绍 4.7.2血液制品业务 4.8上海生物制品研究所 4.8.1公司介绍 4.8.2血液制品业务 4.9山西康宝生物制品股份有限公司 4.9.1公司介绍 4.9.2血液制品业务 4.10绿十字 4.10.1公司介绍 4.10.2血液制品业务 4.11 武汉人福医药集团股份有限公司 4.11.1公司简介 4.11.2 经营状况 4.11.3 血液制品(武汉中原瑞德生物制品有限责任公司) 4.12 云南沃森生物技术股份有限公司 4.12.1 公司简介 4.12.2 经营状况 4.12.3 血液制品(河北大安制药有限公司)
1. Profile of Blood Products
1.1 Definition
1.2 Classification
1.3 Recombinant Blood Products
1.4 Industry Chain
1.5 Features
2. Overview of China Blood Products Industry
2.1 Market Size
2.2 Development Status
2.3 Supply & Demand
2.3.1 Supply
2.3.2 Demand
2.4 Market Competition
2.5 Operating Environment
2.5.1 International Market
2.5.2 Policies
2.5.3 Domestic Biopharmaceutical Market
2.6 Import & Export
3. Blood Product Market Segments in China
3.1 Human Albumin
3.1.1 Supply & Demand
3.1.2 Competition Pattern
3.1.3 Prospects
3.2 Human Immunoglobulin (pH4) for Intravenous Injection
3.2.1 Supply & Demand
3.2.2 Competition Pattern
3.3 Coagulation Factor VIII
3.3.1 Supply & Demand
3.3.2 Competition Pattern
3.3.3 Prospects
3.4 Hepatitis B Immunoglobulin
3.4.1 Supply & Demand
3.4.2 Competition Pattern
3.5 Human Immunoglobulin
3.5.1 Supply & Demand
3.5.2 Competition Pattern
3.6 Human Prothrombin Complex
3.6.1 Supply & Demand
3.6.2 Competition Pattern
3.7 Tetanus Immunoglobulin
3.7.1 Supply & Demand
3.7.2 Competition Pattern
3.8 Rabies Immunoglobulin
3.8.1 Supply & Demand
3.8.2 Competition Pattern
4. Key Companies in China
4.1 China Biologic Products Inc.
4.1.1 Profile
4.1.2 Operation
4.1.3 Revenue Structure
4.1.4 Clients and Suppliers
4.1.5 R&D and Investment
4.1.6 Shandong Taibang Biological Products Co., Ltd.
4.1.7 Guiyang Qianfeng Biological Products Co., Ltd.
4.1.8 Xi’an Hui Tian Blood Products Co., Ltd.
4.1.9 Development and Prospects
4.2 Hualan Biological Engineering Inc.
4.2.1 Profile
4.2.2 Operation
4.2.3 Revenue Structure
4.2.4 Gross Margin
4.2.5 Clients and Suppliers
4.2.6 R&D and Investment
4.2.7 Blood Products
4.2.8 Development and Prospects
4.3 Shanghai RAAS Blood Products Co., Ltd.
4.3.1 Profile
4.3.2 Operation
4.3.3 Revenue Structure
4.3.4 Gross Margin
4.3.5 Clients and Suppliers
4.3.6 R&D and Investment
4.3.7 Development and Prospects
4.4 Beijing Tiantan Biological Products Co., Ltd.
4.4.1 Profile
4.4.2 Operation
4.4.3 Revenue Structure
4.4.4 Clients and Suppliers
4.4.5 Gross Margin
4.4.6 R&D and Investment
4.4.7 Blood Products (Chengdu Ronsen Pharmaceutical Co., Ltd.)
4.4.8 Development and Prospects
4.5 Zhenxing Biopharmaceutical & Chemical Inc.
4.5.1 Profile
4.5.2 Operation
4.5.3 Revenue Structure
4.5.4 Gross Margin
4.5.5 Clients and Suppliers
4.5.6 R&D and Investment
4.5.7 Blood Products (Guangdong Shuanglin Bio-Pharmacy Co., Ltd.)
4.5.8 Development and Prospects
4.6 Jiangxi Boya Biopharmaceutical Co., Ltd.
4.6.1 Profile
4.6.2 Operation
4.6.3 Revenue Structure
4.6.4 Gross Margin
4.6.5 Clients and Suppliers
4.6.6 R&D and Investment
4.6.7 Development and Prospects
4.7 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
4.7.1 Profile
4.7.2 Blood Products
4.8 CNBG Shanghai Institute of Biological Products
4.8.1 Profile
4.8.2 Blood Products
4.9 Shanxi Kangbao Biological Product Co., Ltd.
4.9.1 Profile
4.9.2 Blood Products
4.10 Green Cross
4.10.1 Profile
4.10.2 Blood Products
4.11 Humanwell Healthcare (Group) Co., Ltd.
4.11.1 Profile
4.11.2 Operation
4.11.3 Blood Products (Wuhan Zhongyuan Ruide Biological Products Co., Ltd.)
4.12 Walvax Biotechnology Co, Ltd.
4.12.1 Profile
4.12.2 Operation
4.12.3 Blood Products (Hebei Daan Pharmaceutical Co., Ltd.)
图:血液的基本组成 表:血液制品的分类及作用 表:基因重组类血制品与传统血制品对比 表:国内外重组血液制品产品种类及对比 图:血液制品产业链 图:2003-2015E年中国血液制品市场规模(单位:十亿元) 表:2013年中国部分血液制品价格 表:2007-2012年中国血液制品(分产品)批签发量(单位:千瓶) 图:2009-2012年中国血液制品产品结构(按批签发量计) 图:2002-2012年中国年投浆量(单位:吨) 图:截止2013年6中国血浆站资源地域分布 表:中国主流血液制品医保覆盖情况 表:中国与发达国家血液制品人均使用量的对比 表:2012年中国主要血液制品企业血浆站分布、投浆量及血液制品业务收入 表:国内血液制品生产企业产品线对比 图:全球血液制品产品结构 表:国外上市的血液制品 表:目前国外正在进行的新适应症临床试验 表:全球血液制品生产商 表:中国血液制品主要政策 图:2008-2012年中国生物生化制造行业工业销售产值和利润总额 图:2003-2012年中国人血白蛋白价格 图:2007-2012年中国人血白蛋白国产与进口比例(按批签发量计) 表:2008-2012年中国人血白蛋白主要厂商市场份额(按批签发量计) 表:2010年中国与美国静注人免疫球蛋白消耗量比较 图:2007-2012年中国静丙(ph4)的批签发数量及增长率(单位:千瓶) 图:中国与其他国家静丙(ph4)价格对比 图:2007-2012年中国静注人免疫球蛋白主要厂商市场份额(按批签发量计) 图:2008-2012年中国凝血因子VIII批签发数量及增长率(单位:千瓶) 图:2008-2012年中国人凝血因子VIII厂商市场份额(按批签发量计) 表:人源性凝血因子VIII与重组凝血因子VIII的比较 图:2008-2012年中国乙肝免疫球蛋白的批签发数量及增长率(单位:千瓶) 图:2008-2012年中国乙肝免疫球蛋白市场主要厂商市场份额(按批签发量计) 表:2013年中国各剂型人免疫球蛋白价格 图:2008-2012年中国人免疫球蛋白批签发数量及增长率(单位:千瓶) 图:2008-2012年中国人免疫球蛋白批签发量主要厂商市场份额(按批签发量计) 图:2009-2012年中国人凝血酶原复合物批发签量及增长率(单位:千瓶) 图:2008-2012年中国人凝血酶原复合物厂商市场份额(按批签发量计) 图:2008-2012年中国破伤风免疫球蛋白批签发数量及增长率(单位:千瓶) 图:2008-2012年中国破伤风免疫球蛋白主要厂商市场份额(按批签发数量计) 图:2008-2012年中国狂犬病人免疫球蛋白批签发数量及增长率(单位:千瓶) 图:2008-2012年中国狂犬病人免疫球蛋白主要厂商市场份额(按批签发量计) 图:截止2012年中国生物制品股权结构图 图:2007-2012年中国生物制品营业收入和营业利润(单位:百万美元) 表:2011-2012年中国生物制品(分产品)营业收入 图:2010-2012年中国生物制品(分产品)营业收入构成 图:2008-2012年中国生物制品前五客户收入贡献及占总营业收入的比重 图:2010-2012年中国生物制品研发投入及占营业收入的比重 表:截止2012年底中国生物制品在研新品 表:2008-2012年山东泰邦血液制品批签发量 表:2007-2011年贵阳黔峰血液制品批签发量(单位:千瓶) 表:2008-2012年西安回天血液制品批签发量 图:2012-2015年中国生物制品营业收入与营业利润 图:2007-2012年华兰生物营业收入和利润总额(单位:百万元) 表:2007-2012年华兰生物(分行业)营业收入 表:2007-2012年华兰生物(分产品)营业收入(单位:百万元) 表:2007-2012年华兰生物(分地区)营业收入(单位:百万元) 图: 2007-2012年华兰生物(分行业)毛利率 表:2007-2012年华兰生物(分产品)毛利率 图:2007-2012年华兰生物前五客户收入贡献及占总营业收入的比重 图:2007-2012年华兰生物前五供应商采购金额及占总采购金额的比重 图:2007-2012年华兰生物研发投入及占总营业收入的比重 表:华兰生物血液制品种类及规格 表:截止2013年5月华兰生物采浆占分布 表:2008-2012年华兰生物血液制品批发签量(单位:千瓶) 图:2007-2012年华兰生物血液制品营业收入及毛利率(单位:百万元) 表:2007-2012年华兰生物血液制品(分产品)营业收入及毛利率 图:2012-2015年华兰生物营业收入与营业利润 表:截止2012年底上海莱士血浆站分布情况 图:2007-2012年上海莱士营业收入和营业利润 表:2008- 2012 年上海莱士血液制品批发签量 图:2007-2012年上海莱士(分产品)营业收入 表: 2007-2012年上海莱士(分地区)营业收入 图:2007-2012年上海莱士(分产品)毛利率 图:2007-2012年上海莱士前五客户收入贡献及其占比 表:2012年上海莱士前五客户名称、收入贡献及其占比 图:2007-2012年上海莱士前五供应商采购额占总采购金额的比重 图:2007-2012年上海莱士研发投入及占营业收入的比重 图:2012-2015年上海莱士营业收入与营业利润预测 表:2012年天坛生物主要参股公司及其营收、净利润(Unit:RMB mIn) 图:2007-2012年天坛生物营业收入和利润总额 图:2007-2012年天坛生物(分行业)营业收入 表:2007-2012年天坛生物(分地区)营业收入 图: 2007-2012年天坛生物(分行业)毛利率 图:2007-2012年天坛生物前五供应商及其采购金额占总采购金额比重 图:2007-2012年天坛生物前五客户收入贡献及占总营业收入的比重 表:2012年天坛生物前五客户名称、收入贡献及其占比 图:2009-2012年天坛生物研发成本及占营业收入的比重 表:截至2012年底天坛生物采浆站分布 图:2007-2012年天坛生物血液制品营业收入及毛利率 表:2008-2012年成都蓉生和天坛重庆血液制品批发签量 (单位: 千瓶) 图:2012-2015年天坛生物营业收入与营业利润 图:2009-2012年ST生化营业收入与营业利润 表:2009-2012年ST生化(分产品)主营业收入 图:2009-2012年ST生化(分地区)主营业收入 表:2009-2012年ST生化(分产品)毛利率 图:2009-2012年ST生化前五客户收入贡献及占同期营业收入的比重 表:2012年ST生化前五客户名称、收入贡献及其占同期营业收入的比重 表:2012年ST生化前五供应商名称、采购金额 及占同期采购总额的比重 图:2009-2012年ST生化研发投入及占同期营业收入的比重 表:截至2012年底ST生化在研产品进度 图:2010-2012年双林生物投浆量 表:截至2012年底双林生物采浆站分布 表:2011-2012年ST生化血液制品产量、销量及库存量 表:2008-2012年双林生物血液制品批发签量 图:2009-2012年ST生化血液制品营业收入与毛利率 图:2012-2015年ST生化营业收入与营业利润预测 图:2008-2012年博雅生物采浆量 图:2009-2012年博雅生物营业收入和营业利润(单位:百万元) 表:2009-2012年博雅生物(分产品)营业收入 表:2011-2012年博雅生物血液制品批签发量 表:2009-2012年博雅生物(分地区)营业收入 图:2009-2012年博雅生物(分产品)毛利率 图:2009-2012年博雅生物前五客户收入贡献及占总营业收入的比重(单位:百万元) 表:2012年博雅生物前五客户名称、收入贡献及占比 图:2009-2012年博雅生物前五供应商采购金额及占总采购金额的比重 图:2009-2012年博雅生物研发投入及占营业收入比重 图:2012-2015年博雅生物营业收入与营业利润预测 表:截止2012年底蜀阳药业血浆站分布 表:2008-2012年远大蜀阳血液制品批签发量(单位:千瓶) 表:2008-2012年上海所血液制品批签发量(单位:千瓶) 表:截止2012年底上海所血浆站分布 表:截止2012年底山西康宝血浆站分布 表:2008-2012年康宝生物血液制品批签发量 表:截止2012年底绿十字(中国)血浆站分布 表:2008-2012年绿十字(中国)血液制品批签发量(单位:千瓶) 图:2007-2012年人福医药营业收入与营业利润 表:2008-2012年武汉瑞德血液制品批发签量 图:沃森生产产业布局 图:2007-2012年沃森生物营业收入与营业利润
Basic Composition of Blood Classification and Application of Blood Products Comparison between Recombinant Blood Products and Conventional Blood Products Classification and Comparison of Domestic and Foreign Recombinant Blood Products Blood Product Industry Chain China’s Blood Product Market Size, 2003-2015E Prices of Some Blood Products in China, 2013 Lot Release Volume of Blood Products in China (by Product), 2007-2012 China’s Blood Product Structure (by Lot Release Volume), 2009-2012 China’s Plasma Volume, 2002-2012 Plasma Station Distribution in China by Region, Jun 2013 Health Insurance Coverage of Mainstream Blood Products in China Comparison between China and Developed Countries by Per Capita Consumption of Blood Products Plasma Station Distribution, Plasma Volume and Blood Product Revenue of Major Blood Product Enterprises in China, 2012 Comparison among Domestic Blood Product Producers by Product Line Global Blood Product Structure Blood Products Available in Foreign Markets Ongoing Clinical Trials of New Indications in Foreign Countries Global Producers of Blood Products Main Policies for Blood Products in China Industrial Sales Output Value and Total Profit of China’s Biological and Biochemical Manufacturing Industry, 2008-2012 Human Serum Albumin Prices in China, 2003-2012 Domestic and Imported Human Serum Albumin in China (by Lot Release Volume), 2007-2012 Market Share of Major Producers of Human Serum Albumin in China (by Lot Release Volume), 2008-2012 Comparison between China and USA by Consumption of Human Immunoglobulin for Intravenous Injection, 2010 Lot Release Volume and Growth Rate of Human Immunoglobulin (pH4) for Intravenous Injection in China, 2007-2012 Comparison between China and Other Countries by Price of Human Immunoglobulin (pH4) for Intravenous Injection Market Share of Major Producers of Human Immunoglobulin (pH4) for Intravenous Injection in China (by Lot Release Volume), 2007-2012 Lot Release Volume and Growth Rate of Coagulation Factor VIII in China, 2008-2012 Market Share of Human Coagulation Factor VIII Producers in China (by Lot Release Volume), 2008-2012 Comparison between Human-derived Coagulation Factor VIII and Recombinant Coagulation Factor VIII Lot Release Volume and Growth Rate of Hepatitis B Immunoglobulin in China, 2008-2012 Market Share of Major Hepatitis B Immunoglobulin Enterprises in China (by Lot Release Volume), 2008-2012 Prices of Human Immunoglobulin in China by Dosage Form, 2013 Lot Release Volume and Growth Rate of Human Immunoglobulin in China, 2008-2012 Market Share of Major Human Immunoglobulin Enterprises in China (by Lot Release Volume), 2008-2012 Lot Release Volume and Growth Rate of Human Prothrombin Complex in China, 2009-2012 Market Share of Human Prothrombin Complex Enterprises in China (by Lot Release Volume), 2008-2012 Lot Release Volume and Growth Rate of Tetanus Immunoglobulin in China, 2008-2012 Market Share of Major Tetanus Immunoglobulin Enterprises in China (by Lot Release Volume), 2008-2012 Lot Release Volume and Growth Rate of Rabies Immunoglobulin in China, 2008-2012 Market Share of Major Rabies Immunoglobulin Enterprises in China (by Lot Release Volume), 2008-2012 Shareholding Structure of China Biologic Products, 2012 Revenue and Operating Income of China Biologic Products, 2007-2012 Revenue of China Biologic Products (by Product), 2011-2012 Revenue Structure of China Biologic Products (by Product), 2010-2012 Revenue Contribution and % of Total Revenue of China Biologic Products’ Top Five Customers, 2008-2012 R&D Investment and % of Revenue of China Biologic Products, 2010-2012 New Products under Research by China Biologic Products, 2012 Lot Release Volume of Blood Products of Shandong Taibang, 2008-2012 Lot Release Volume of Blood Products of Guiyang Qianfeng, 2007-2011 Lot Release Volume of Blood Products of Xi’an Hui Tian, 2008-2012 Revenue and Operating Income of China Biologic Products, 2012-2015 Revenue and Total Profit of Hualan Biological Engineering, 2007-2012 Revenue of Hualan Biological Engineering (by Sector), 2007-2012 Revenue of Hualan Biological Engineering (by Product), 2007-2012 Revenue of Hualan Biological Engineering (by Region), 2007-2012 Gross Margin of Hualan Biological Engineering (by Sector), 2007-2012 Gross Margin of Hualan Biological Engineering (by Product), 2007-2012 Revenue Contribution and % of Total Revenue of Hualan Biological Engineering’s Top Five Customers, 2007-2012 Procurement of Hualan Biological Engineering from Top Five Suppliers, 2007-2012 R&D Investment and % of Total Revenue of Hualan Biological Engineering, 2007-2012 Blood Product Types and Specifications of Hualan Biological Engineering Plasma Collection Distribution of Hualan Biological Engineering, May 2013 Lot Release Volume of Blood Products of Hualan Biological Engineering, 2008-2012 Blood Product Revenue and Gross Margin of Hualan Biological Engineering, 2007-2012 Blood Product Revenue and Gross Margin of Hualan Biological Engineering (by Product), 2007-2012 Revenue and Operating Income of Hualan Biological Engineering, 2012-2015E Plasma Station Distribution of Shanghai RAAS, 2012 Revenue and Operating Income of Shanghai RAAS, 2007-2012 Lot Release Volume of Blood Products of Shanghai RAAS, 2008-2012 Revenue of Shanghai RAAS (by Product), 2007-2012 Revenue of Shanghai RAAS (by Region), 2007-2012 Gross Margin of Shanghai RAAS (by Product), 2007-2012 Revenue Contribution of Shanghai RAAS’ Top Five Customers, 2007-2012 Name List and Revenue Contribution of Shanghai RAAS’ Top Five Customers, 2012 Procurement of Shanghai RAAS from Top Five Suppliers, 2007-2012 R&D Costs and % of Revenue of Shanghai RAAS, 2007-2012 Revenue and Operating Income of Shanghai RAAS, 2012-2015E Major Subsidiaries and Their Revenue and Net Income of Beijing Tiantan Biological Products, 2012 Revenue and Total Profit of Beijing Tiantan Biological Products, 2007-2012 Revenue of Beijing Tiantan Biological Products (by Sector), 2007-2012 Revenue of Beijing Tiantan Biological Products (by Region), 2007-2012 Gross Margin of Beijing Tiantan Biological Products (by Sector), 2007-2012 Procurement of Beijing Tiantan Biological Products from Top Five Suppliers, 2007-2012 Revenue Contribution and % of Total Revenue of Beijing Tiantan Biological Products’ Top Five Customers, 2007-2012 Name List and Revenue Contribution of Beijing Tiantan Biological Products’ Top Five Customers, 2012 R&D Costs and % of Revenue of Beijing Tiantan Biological Products, 2009-2012 Plasma Station Distribution of Beijing Tiantan Biological Products, 2012 Blood Product Revenue and Gross Margin of Beijing Tiantan Biological Products, 2007-2012 Lot Release Volume of Blood Products of Chengdu Ronsen and Tiantan Chongqing, 2008-2012 Revenue and Operating Income of Beijing Tiantan Biological Products, 2012-2015 Revenue and Operating Income of Zhenxing Biopharmaceutical & Chemical, 2009-2012 Operating Revenue of Zhenxing Biopharmaceutical & Chemical (by Product), 2009-2012 Operating Revenue of Zhenxing Biopharmaceutical & Chemical (by Region), 2009-2012 Gross Margin of Zhenxing Biopharmaceutical & Chemical (by Product), 2009-2012 Revenue Contribution of Zhenxing Biopharmaceutical & Chemical’s Top Five Customers, 2009-2012 Name List and Revenue Contribution of Zhenxing Biopharmaceutical & Chemical’s Top Five Customers, 2012 Procurement of Zhenxing Biopharmaceutical & Chemical from Top Five Suppliers, 2012 R&D Costs and % of Revenue of Zhenxing Biopharmaceutical & Chemical, 2009-2012 R&D Progress of Zhenxing Biopharmaceutical & Chemical, 2012 Plasma Volume of Shuanglin Bio-pharmacy, 2010-2012 Plasma Station Distribution of Shuanglin Bio-pharmacy, 2012 Blood Product Output, Sales Volume and Inventory of Zhenxing Biopharmaceutical & Chemical, 2011-2012 Lot Release Volume of Blood Products of Shuanglin Bio-pharmacy, 2008-2012 Blood Product Revenue and Gross Margin of Zhenxing Biopharmaceutical & Chemical, 2009-2012 Revenue and Operating Income of Zhenxing Biopharmaceutical & Chemical, 2012-2015E Plasma Collection Volume of Jiangxi Boya Bio-pharmaceutical, 2008-2012 Revenue and Operating Income of Jiangxi Boya Bio-pharmaceutical, 2009-2012 Revenue of Jiangxi Boya Bio-pharmaceutical (by Product), 2009-2012 Lot Release Volume of Blood Products of Jiangxi Boya Bio-pharmaceutical, 2011-2012 Revenue of Jiangxi Boya Bio-pharmaceutical (by Region), 2009-2012 Gross Margin of Jiangxi Boya Bio-pharmaceutical (by Product), 2009-2012 Revenue Contribution and % of Total Revenue of Jiangxi Boya Bio-pharmaceutical’s Top Five Customers, 2009-2012 Name List and Revenue Contribution of Jiangxi Boya Bio-pharmaceutical’s Top Five Customers, 2012 Procurement of Jiangxi Boya Bio-pharmaceutical from Top Five Suppliers, 2009-2012 R&D Costs and % of Revenue of Jiangxi Boya Bio-pharmaceutical, 2009-2012 Revenue and Operating Income of Jiangxi Boya Bio-pharmaceutical, 2012-2015E Plasma Station Distribution of Sichuan Yuanda Shuyang Pharmaceutical, 2012 Lot Release Volume of Blood Products of Sichuan Yuanda Shuyang Pharmaceutical, 2008-2012 Lot Release Volume of Blood Products of CNBG Shanghai Institute of Biological Products, 2008-2012 Plasma Station Distribution of CNBG Shanghai Institute of Biological Products, 2012 Plasma Station Distribution of Shanxi Kangbao Biological Product, 2012 Lot Release Volume of Blood Products of Shanxi Kangbao Biological Product, 2008-2012 Plasma Station Distribution of Green Cross China, 2012 Lot Release Volume of Blood Products of Green Cross China, 2008-2012 Revenue and Operating Income of Humanwell Healthcare, 2007-2012 Lot Release Volume of Blood Products of Wuhan Zhongyuan Ruide Biological Products, 2008-2012 Industrial Distribution of Walvax Biotechnology Revenue and Operating Income of Walvax Biotechnology, 2007-2012
如果这份报告不能满足您的要求,我们还可以为您定制报告,请 留言说明您的详细需求。
|